Norges Bank Takes Position in Upstream Bio, Inc. $UPB

Norges Bank acquired a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,882,647 shares of the company’s stock, valued at approximately $78,264,000. Norges Bank owned about 5.33% of Upstream Bio as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the stock. Invesco Ltd. raised its holdings in shares of Upstream Bio by 6.4% during the second quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock valued at $179,000 after purchasing an additional 985 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Upstream Bio during the fourth quarter valued at approximately $29,000. Torren Management LLC purchased a new position in shares of Upstream Bio during the fourth quarter valued at approximately $30,000. JPMorgan Chase & Co. raised its holdings in shares of Upstream Bio by 8.4% during the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after purchasing an additional 1,275 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Upstream Bio by 2.8% during the third quarter. Rhumbline Advisers now owns 49,406 shares of the company’s stock valued at $929,000 after purchasing an additional 1,340 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on UPB. Weiss Ratings cut shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. HC Wainwright started coverage on shares of Upstream Bio in a research report on Wednesday. They set a “buy” rating and a $36.00 target price for the company. Evercore lowered shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a research report on Friday, March 27th. Wall Street Zen lowered shares of Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Mizuho cut their target price on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $38.20.

Upstream Bio Trading Down 5.1%

Shares of NASDAQ UPB opened at $7.05 on Friday. The firm has a 50 day moving average of $9.05 and a 200 day moving average of $17.50. The firm has a market capitalization of $383.66 million, a price-to-earnings ratio of -2.42 and a beta of 1.10. Upstream Bio, Inc. has a 12-month low of $6.98 and a 12-month high of $33.68.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.02). The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.03 million. Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. Sell-side analysts predict that Upstream Bio, Inc. will post -2.99 EPS for the current year.

Upstream Bio Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.